Clinical trials: Sepsis Syndromes
Septic Shock
Effect of Early Administration of Albumin 20% Versus Crystalloid
Sepsis and septic shock are global health problems, leading to a high mortality rate. They are often associated with extremely low blood pressure and multiple organ dysfunctions, which are the main causes of death in critically…
- Trial name
- NCT06370078
- Testing
- Albumin Human
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Egymedicalpedia
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
The purpose of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of CF-301 in addition to background standard of care (SOC) antibacterial therapy for the treatment of Staphylococcus aureus (S.
- Trial name
- NCT03163446
- Testing
- CF-301
- Where
- 78 sites in United States, Belgium and 12 more
- Volunteers
- 121 people
- Sponsor
- ContraFect
COVID-19
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS)…
- Trial name
- NCT04351243
- Testing
- Gimsilumab
- Where
- 33 sites in United States
- Volunteers
- 227 people
- Sponsor
- Kinevant Sciences GmbH
Bacteremia
Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia
The purpose of this study is to assess the safety and efficacy of ceftobiprole versus a comparator in hospitalized patients with bacteremia.
- Trial name
- NCT00505258
- Testing
- ceftobiprole medocaril
- Sponsor
- Basilea Pharmaceutica
Sepsis
Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients
Phase II study of Kukoamine B Mesilate in Sepsis Patients
- Trial name
- NCT04803955
- Testing
- 16mg，KB
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Tianjin Chasesun Pharmaceutical Co., LTD
Severe Sepsis
Symphony IL-6 Cutoff Validation Study for Patients at Risk of Severe Sepsis
Symphony IL-6 is a device that quantitates human IL-6 by fluorescence enzyme immunoassay (FEIA) from whole-blood specimens. Use of Symphony IL- 6 removes the need for plasma separation before testing.
- Trial name
- NCT05048927
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Bluejay Diagnostics, Inc.
Sepsis
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploration Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Characteristics of STC314 Injection Administered Intravenously in Sepsis Patients
One study evaluated the efficacy and safety of intravenous STC314 injection in patients with sepsis Sex and pharmacokinetic profiles of a multicenter, randomized, double-blind, placebo-controlled II Phase I dose exploration…
- Trial name
- Sepsis (NCT06548854)
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Grand Medical Pty Ltd.
Sepsis, SIRS
The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS
A non-interventional, prospective observational study to assess the performance of SeptiCyte® Lab to diagnose patients identified as suspected of sepsis in general medical and surgical wards with infection-positive from…
- Trial name
- NCT02704871
- Testing
- SeptiCyte Lab molecular diagnostic test (non-interventional)
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Immunexpress
Septic Shock
Efferon LPS Hemoperfusion for Treatment of Patients With Septic Shock
Sepsis is a global healthcare burden sepsis, it reaches 20-30 million cases annually (WHO data). Numerous studies have shown that extracorporeal hemoperfusion therapies that eliminate endotoxin and\or excess of cytokines improve…
- Trial name
- NCT04884854
- Testing
- Efferon LPS
- Where
- Russia
- Volunteers
- 9 people
- Sponsor
- Efferon JSC
Sepsis, Community Acquired Pneumonia (CAP)
OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis
OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to…
- Trial name
- NCT06669403
- Testing
- OPT101
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Op-T LLC
Biomarkers, Acute Kidney Injury
Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid
The goal of this observational study is to understand whether a wearable sensor (the Nutromics Sensor Device) can accurately measure drug and biomarker levels in the fluid just under the skin (interstitial fluid), instead of…
- Conditions
- Biomarkers, Acute Kidney Injury, Sepsis
- Trial name
- VENTURE (NCT07893223)
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Nutromics
Catecholamine Resistant Hypotension (CRH), Distributive Shock
Expanded Access for LJPC-501
The primary objective of the study is to provide access to LJPC-501 for distributive shock patients who remain hypotensive despite receiving fluid and vasopressor therapy.
- Conditions
- Catecholamine Resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
- Trial name
- NCT03245528
- Testing
- LJPC-501
- Sponsor
- La Jolla Pharmaceutical Company
Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia
Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia
This is a study of safety and efficacy of ceftaroline fosamil in Subjects with Staphylococcus aureus Bacteremia or with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia persisting after at least 72 hours of…
- Trial name
- NCT01701219
- Testing
- Ceftaroline fosamil
- Where
- 27 sites in United States
- Volunteers
- 56 people
- Sponsor
- Forest Laboratories
Sepsis, Septic Shock
Predictive algoRithm for EValuation and Intervention in SEpsis
In this prospective study, the ability of a machine learning algorithm to predict sepsis and influence clinical outcomes, will be investigated at Cabell Huntington Hospital (CHH).
- Conditions
- Sepsis, Septic Shock, Severe Sepsis
- Trial name
- PREVISE (NCT03235193)
- Testing
- Severe Sepsis Prediction, Severe Sepsis Detection
- Where
- United States
- Volunteers
- 2,296 people
- Sponsor
- Dascena
Sepsis, Hypotension
Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion
The purpose of this study is to determine whether continued administration of Drotrecogin Alfa (Activated) up to additional 72 hours - after the so far recommended 96 hour infusion period - results in a more rapid resolution of…
- Trial name
- NCT00190788
- Testing
- Drotrecogin Alfa (Activated)
- Where
- 2 sites in United States, France
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Infection
Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance
This study is a post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Ciproxan intravenously as a first-line treatment for sepsis, secondary skin infections…
- Trial name
- NCT01670435
- Testing
- Ciprofloxacin (BAYQ3939)
- Where
- Japan
- Volunteers
- 3,274 people
- Sponsor
- Bayer
Sepsis
Integration of NAVOY® Sepsis in an Electronic Health Record System
The study aims to evaluate the performance of NAVOY® Sepsis in predicting the sepsis risk in adult ICU patients. Data collection is performed via automatic retrieval from the electronic health record system to AlgoDx proprietary…
- Trial name
- GENIUS (NCT05095220)
- Where
- Sweden
- Volunteers
- 1,000 people
- Sponsor
- AlgoDx
Sars-CoV2
Rhu-pGSN for Severe Covid-19 Pneumonia
Study Objectives: Primary To assess the efficacy (survival without organ failure on Day 14) of three doses of rhu-pGSN administered intravenously (IV) plus standard of care (SOC) to hospitalized subjects with a primary diagnosis…
- Trial name
- NCT04358406
- Testing
- Recombinant human plasma gelsolin (Rhu-pGSN)
- Where
- 3 sites in Romania, Spain
- Volunteers
- 64 people
- Sponsor
- BioAegis Therapeutics Inc.
Sepsis, Renal Failure
The Prevention of Failure to Rescue Using Early Warning Scoring
The purpose of this study is to assess if, compared with standard paper-based systems, an automated Early Warning System (EWS) resident in a spot check patient monitor, can help to identify deteriorating patients.
- Conditions
- Sepsis, Renal Failure, Pulmonary Edema, Cardio-pulmonary Arrest
- Trial name
- VitalCare (NCT01197326)
- Testing
- use of the MP5 EWS patient monitor
- Where
- Australia
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- Philips Healthcare
Shock, Septic
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock
This is a randomised, double-blind, two-stage, placebo controlled study. It is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of 3 doses of nangibotide versus placebo in adult patients…
- Trial name
- NCT03158948
- Testing
- Nangibotide 0.3 mg/kg, Nangibotide 1 mg/kg, Nangibotide 3 mg/kg
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 50 people
- Sponsor
- Inotrem